PHARMACOKINETICS OF GABAPENTIN IN SUBJECTS WITH VARIOUS DEGREES OF RENAL-FUNCTION

被引:103
作者
BLUM, RA
COMSTOCK, TJ
SICA, DA
SCHULTZ, RW
KELLER, E
REETZE, P
BOCKBRADER, H
TUERCK, D
BUSCH, JA
REECE, PA
SEDMAN, AJ
机构
[1] MILLARD FILLMORE HOSP,DEPT MED,BUFFALO,NY
[2] VIRGINIA COMMONWEALTH UNIV,DEPT PHARM & PHARMACEUT,RICHMOND,VA
[3] VIRGINIA COMMONWEALTH UNIV,DEPT MED,RICHMOND,VA
[4] UNIV KLIN FREIBURG,DEPT INNERE MED 4,FREIBURG,GERMANY
[5] GODECKE AG,DEPT PHARMACOKINET,FREIBURG,GERMANY
[6] GODECKE AG,DEPT DRUG METAB,FREIBURG,GERMANY
[7] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CLIN PHARMACOL,ANN ARBOR,MI 48105
[8] WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT PHARMACOKINET & DRUG METAB,ANN ARBOR,MI 48105
关键词
D O I
10.1038/clpt.1994.118
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics of oral gabapentin (400 mg) was studied in normal subjects and in subjects with various degrees of renal function. Sixty subjects participated in this three-center study. None of the subjects were receiving hemodialysis. Plasma and urine samples were collected for up to 264 hours after dosing, and concentrations of gabapentin were determined by high performance liquid chromatography. Apparent oral plasma clearance (CL/F) and renal clearance (CIR) of gabapentin decreased and maximum plasma concentration, time to reach maximum concentration, and half-life values increased as renal function diminished. Gabapentin CL/F and CL(R) were linearly correlated with creatinine clearance. Total urinary recovery of unchanged drug was comparable in all subjects, indicating that the extent of drug absorption was unaffected by renal function. There was no evidence of gabapentin metabolism even in subjects with severe renal impairment. In summary, impaired renal function results in higher plasma gabapentin concentrations, longer elimination half-lives, and reduced CL/F and CL(R) values. Based on pharmacokinetic considerations, it appears that the dosing regimen of gabapentin in subjects with renal impairment may be adjusted on the basis of creatinine clearance.
引用
收藏
页码:154 / 159
页数:6
相关论文
共 12 条
[1]  
BARTOSZYK GD, 1986, CURRENT PROBLEMS EPI, V4, P147
[2]   GABAPENTIN AS AN ANTIEPILEPTIC DRUG IN MAN [J].
CRAWFORD, P ;
GHADIALI, E ;
LANE, R ;
BLUMHARDT, L ;
CHADWICK, D .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1987, 50 (06) :682-686
[3]   DETERMINATION OF GABAPENTIN IN PLASMA AND URINE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND PRE-COLUMN LABELING FOR ULTRAVIOLET DETECTION [J].
HENGY, H ;
KOLLE, EU .
JOURNAL OF CHROMATOGRAPHY, 1985, 341 (02) :473-478
[4]   VALIDITY OF CREATININE CLEARANCE ESTIMATES IN THE ASSESSMENT OF RENAL-FUNCTION [J].
LUKE, DR ;
HALSTENSON, CE ;
OPSAHL, JA ;
MATZKE, GR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 48 (05) :503-508
[5]   USING SERUM CREATININE CONCENTRATIONS TO SCREEN FOR INAPPROPRIATE DOSAGE OF RENALLY ELIMINATED DRUGS [J].
PETERSON, JP ;
COLUCCI, VJ ;
SCHIFF, SE .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1991, 48 (09) :1962-1964
[6]  
SCHMIDT B, 1989, ANTIEPILEPTIC DRUGS, P925
[8]   DOUBLE-BLIND-STUDY OF GABAPENTIN IN THE TREATMENT OF PARTIAL SEIZURES [J].
SIVENIUS, J ;
KALVIAINEN, R ;
YLINEN, A ;
RIEKKINEN, P .
EPILEPSIA, 1991, 32 (04) :539-542
[9]   PITFALLS OF PHARMACOKINETIC DOSAGE GUIDELINES IN RENAL-INSUFFICIENCY [J].
TURNHEIM, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (01) :87-93
[10]   CREATININE CLEARANCE DURING CIMETIDINE ADMINISTRATION FOR MEASUREMENT OF GLOMERULAR-FILTRATION RATE [J].
VANACKER, BAC ;
KOOMEN, GCM ;
KOOPMAN, MG ;
DEWAART, DR ;
ARISZ, L .
LANCET, 1992, 340 (8831) :1326-1329